Want to see AU:AT1 full AI Analyst Report?
AT1 Stock Chart & Stats
AU$0.04
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume312.94K
Average Volume (3M)1.80M
Market Cap
AU$15.34M
Enterprise ValueAU$13.46M
Total Cash (Recent Filing)AU$3.51M
Total Debt (Recent Filing)AU$754.39K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.96M
Bulls Say, Bears Say
Bulls Say
Proprietary Platform And B2B ModelAtomo's proprietary integrated RDT device and platform underpin a B2B commercial model supplying diagnostic brands and manufacturers. This durable asset allows recurring product development, customization and OEM supply revenues, supporting scalable contracts and margin capture as partners adopt the platform.
Low Financial LeverageA very low debt-to-equity ratio gives Atomo financial flexibility to endure operating volatility and invest in product development without large interest burdens. This capital structure reduces refinancing risk and preserves optionality to fund commercialization or scale manufacturing through equity or retained cash.
Solid Gross Margin LevelA near-50% gross margin indicates attractive unit economics for the device and consumables business. If sales scale or fixed costs are controlled, this margin profile provides a durable pathway to absorb SG&A and R&D and move toward operating profitability as volumes and partner contracts grow.
Bears Say
Declining RevenueA sustained revenue decline reduces scale benefits and increases per-unit fixed cost absorption. For a platform-dependent business, falling sales may signal weaker partner demand or slower adoption, constraining the company's ability to leverage its gross margins and delaying progress toward sustained profitability over the next several months.
Large Operating LossesExtremely negative EBIT and net margins show core operations currently destroy value, requiring meaningful revenue growth or material cost reduction to reach break-even. Persistent wide losses erode equity returns and force ongoing funding needs, undermining long-term financial sustainability if not addressed.
Deteriorating Cash FlowNegative operating cash flow and steep FCF decline materially limit internal funding for commercialization and R&D. This weak cash generation increases reliance on external capital, raising dilution or refinancing risk and constraining the firm's ability to scale manufacturing and partner programs over the next 2-6 months.
Atomo Diagnostics Ltd. News
AT1 FAQ
What was Atomo Diagnostics Ltd.’s price range in the past 12 months?
Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is Atomo Diagnostics Ltd.’s market cap?
Atomo Diagnostics Ltd.’s market cap is AU$15.34M.
When is Atomo Diagnostics Ltd.’s upcoming earnings report date?
Atomo Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 60 days.
How were Atomo Diagnostics Ltd.’s earnings last quarter?
Currently, no data Available
Is Atomo Diagnostics Ltd. overvalued?
According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued.
Does Atomo Diagnostics Ltd. pay dividends?
Atomo Diagnostics Ltd. does not currently pay dividends.
What is Atomo Diagnostics Ltd.’s EPS estimate?
Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atomo Diagnostics Ltd. have?
Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.
What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:AT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atomo Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
-58.40%
Trailing 12-Months
Asset Growth
2.49%
Trailing 12-Months
Company Description
Atomo Diagnostics Ltd.
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various applications, including COVID-19 detection, HIV screening, pregnancy confirmation, and assessing respiratory conditions.
Technical Analysis
Options Prices
Currently, No data available
---